MANGOCEUTICALS, INC. Files 8-K on Director Changes and Compensation
Ticker: MGRX · Form: 8-K · Filed: Sep 12, 2025 · CIK: 1938046
| Field | Detail |
|---|---|
| Company | Mangoceuticals, INC. (MGRX) |
| Form Type | 8-K |
| Filed Date | Sep 12, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $2.30 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, filing
TL;DR
Mangoceuticals 8-K: Director changes and executive comp updates filed 9/9/25.
AI Summary
On September 9, 2025, MANGOCEUTICALS, INC. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing also includes financial statements and exhibits, though specific details on the compensation or financial figures are not provided in this summary.
Why It Matters
This filing signals potential shifts in the company's leadership and executive pay structure, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: low — The filing is a standard 8-K reporting routine changes and does not indicate immediate financial distress or significant negative events.
Key Players & Entities
- MANGOCEUTICALS, INC. (company) — Registrant
- September 9, 2025 (date) — Date of Earliest Event Reported
FAQ
What specific changes were made to the board of directors?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors,' but the specific names and details of these changes are not elaborated in the provided text.
What are the details of the new compensatory arrangements?
The filing mentions 'Compensatory Arrangements of Certain Officers,' but the specific terms, amounts, or beneficiaries of these arrangements are not detailed in the provided text.
What financial statements are included in this filing?
The filing states that 'Financial Statements and Exhibits' are included, but the specific financial statements or their content are not detailed in the provided text.
What is the principal executive office address for MANGOCEUTICALS, INC.?
The principal executive offices are located at 15110 N. Dallas Parkway, Suite 600, Dallas, Texas, 75248.
What is the IRS Employer Identification Number for MANGOCEUTICALS, INC.?
The IRS Employer Identification Number is 87-3841292.
Filing Stats: 999 words · 4 min read · ~3 pages · Grade level 12.4 · Accepted 2025-09-12 16:33:10
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 Par Value Per Share MGRX The Nasdaq
- $2.30 — term of ten years, an exercise price of $2.30 per share, which was the closing sales
Filing Documents
- form8-k.htm (8-K) — 48KB
- ex10-2.htm (EX-10.2) — 84KB
- 0001493152-25-013213.txt ( ) — 313KB
- mgrx-20250909.xsd (EX-101.SCH) — 3KB
- mgrx-20250909_lab.xml (EX-101.LAB) — 33KB
- mgrx-20250909_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 10.1 Second Amended and Restated Mangoceuticals, Inc. 2022 Equity Incentive Plan (Filed as Exhibit 10.2 to the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on March 19, 2025, and incorporated herein by reference) 10.2* Mangoceuticals, Inc. 2022 Equity Incentive Plan Stock Option Agreement dated September 9, 2025 – Jacob Cohen – 500,000 shares 104 Inline XBRL for the cover page of this Current Report on Form 8-K * Certain information has been redacted from the exhibit pursuant to Section (a)(6) of Item 601 of Regulation S-K because the disclosure of such information would constitute an unwarranted invasion of personal privacy.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MANGOCEUTICALS, INC. Date: September 12, 2025 By: /s/ Jacob D. Cohen Jacob D. Cohen Chief Executive Officer